Victory Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $843M | Sell |
1,888,521
-1,468,245
| -44% | -$685M | 0.54% | 23 |
|
|
2025
Q4 | $1.52B | Buy |
3,356,766
+1,109,200
| +49% | +$478M | 0.86% | 14 |
|
|
2025
Q3 | $787M | Buy |
2,247,566
+92,402
| +4% | +$38.6M | 0.46% | 29 |
|
|
2025
Q2 | $968M | Buy |
2,155,164
+1,861,279
| +633% | +$858M | 0.62% | 18 |
|
|
2025
Q1 | $142M | Sell |
293,885
-11,261
| -4% | -$5.25M | 0.15% | 150 |
|
|
2024
Q4 | $123M | Sell |
305,146
-5,268
| -2% | -$2.44M | 0.12% | 180 |
|
|
2024
Q3 | $144M | Sell |
310,414
-15,334
| -5% | -$7.37M | 0.14% | 155 |
|
|
2024
Q2 | $153M | Sell |
325,748
-81,906
| -20% | -$35.6M | 0.15% | 142 |
|
|
2024
Q1 | $170M | Sell |
407,654
-28,184
| -6% | -$11.9M | 0.17% | 133 |
|
|
2023
Q4 | $177M | Sell |
435,838
-142,613
| -25% | -$52.7M | 0.19% | 119 |
|
|
2023
Q3 | $201M | Buy |
578,451
+81,615
| +16% | +$28.5M | 0.23% | 100 |
|
|
2023
Q2 | $175M | Sell |
496,836
-49,703
| -9% | -$16.7M | 0.19% | 113 |
|
|
2023
Q1 | $172M | Buy |
546,539
+51,149
| +10% | +$15.3M | 0.19% | 115 |
|
|
2022
Q4 | $143M | Sell |
495,390
-28,134
| -5% | -$8.57M | 0.16% | 136 |
|
|
2022
Q3 | $152M | Sell |
523,524
-25,868
| -5% | -$7.44M | 0.18% | 132 |
|
|
2022
Q2 | $155M | Buy |
549,392
+27,854
| +5% | +$7.46M | 0.18% | 139 |
|
|
2022
Q1 | $138M | Buy |
521,538
+351,044
| +206% | +$83.3M | 0.14% | 164 |
|
|
2021
Q4 | $37.4M | Buy |
170,494
+4,717
| +3% | +$917K | 0.03% | 667 |
|
|
2021
Q3 | $30.1M | Buy |
165,777
+6,324
| +4% | +$1.23M | 0.03% | 731 |
|
|
2021
Q2 | $32.2M | Sell |
159,453
-413,825
| -72% | -$86.6M | 0.03% | 729 |
|
|
2021
Q1 | $123M | Sell |
573,278
-83,922
| -13% | -$18.4M | 0.13% | 201 |
|
|
2020
Q4 | $155M | Buy |
657,200
+104,471
| +19% | +$24M | 0.17% | 143 |
|
|
2020
Q3 | $150M | Sell |
552,729
-32,147
| -5% | -$8.87M | 0.19% | 125 |
|
|
2020
Q2 | $170M | Sell |
584,876
-464,374
| -44% | -$126M | 0.23% | 94 |
|
|
2020
Q1 | $250M | Buy |
1,049,250
+701,599
| +202% | +$161M | 0.21% | 115 |
|
|
2019
Q4 | $76.1M | Buy |
347,651
+199,395
| +134% | +$40.4M | 0.09% | 314 |
|
|
2019
Q3 | $25.1M | Buy |
148,256
+129,162
| +676% | +$22.8M | 0.03% | 713 |
|
|
2019
Q2 | $3.5M | Buy |
19,094
+67
| +0.4% | +$11.7K | 0.01% | 994 |
|
|
2019
Q1 | $3.5M | Buy |
19,027
+15,258
| +405% | +$2.82M | 0.01% | 944 |
|
|
2018
Q4 | $625K | Sell |
3,769
-25
| -0.7% | -$4.33K | ﹤0.01% | 1313 |
|
|
2018
Q3 | $731K | Sell |
3,794
-46
| -1% | -$8.19K | ﹤0.01% | 1327 |
|
|
2018
Q2 | $653K | Sell |
3,840
-80
| -2% | -$12.4K | ﹤0.01% | 1328 |
|
|
2018
Q1 | $639K | Sell |
3,920
-75
| -2% | -$12.3K | ﹤0.01% | 1317 |
|
|
2017
Q4 | $599K | Sell |
3,995
-166
| -4% | -$24.6K | ﹤0.01% | 1305 |
|
|
2017
Q3 | $633K | Sell |
4,161
-130
| -3% | -$19.6K | ﹤0.01% | 1304 |
|
|
2017
Q2 | $553K | Sell |
4,291
-229
| -5% | -$27.6K | ﹤0.01% | 1295 |
|
|
2017
Q1 | $494K | Sell |
4,520
-144
| -3% | -$12.7K | ﹤0.01% | 1309 |
|
|
2016
Q4 | $344K | Sell |
4,664
-67
| -1% | -$5.45K | ﹤0.01% | 1326 |
|
|
2016
Q3 | $413K | Buy |
4,731
+1,574
| +50% | +$149K | ﹤0.01% | 1290 |
|
|
2016
Q2 | $272K | Sell |
3,157
-68
| -2% | -$5.88K | ﹤0.01% | 1133 |
|
|
2016
Q1 | $256K | Sell |
3,225
-85
| -3% | -$7.69K | ﹤0.01% | 1140 |
|
|
2015
Q4 | $416K | Buy |
+3,310
| New | +$400K | ﹤0.01% | 1071 |
|
|
2013
Q4 | – | Sell |
-4
| Closed | – | – | 1113 |
|
|
2013
Q3 | $0 | Buy |
+4
| New | +$318 | ﹤0.01% | 1374 |
|
Other funds holding VRTX
VCM
VPM
Victory Capital Management's VRTX Position: Q1 2026 in Review
Victory Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 44% in Q1 2026, selling an estimated $685M and leaving 1,888,521 shares worth $843M. The position accounts for 0.54% of the portfolio, ranked #23.
Victory Capital Management first reported a position in VRTX in Q3 2013 and has held it in 43 quarters since. The position peaked at $1.52B in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Victory Capital Management held 1,888,521 shares of Vertex Pharmaceuticals worth $843M as of Q1 2026.
- Victory Capital Management sold 1,468,245 Vertex Pharmaceuticals shares in Q1 2026, an estimated $685M.
- Vertex Pharmaceuticals made up 0.54% of Victory Capital Management's portfolio in Q1 2026, its #23 holding.
- Victory Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 43 quarters since.
- Victory Capital Management's Vertex Pharmaceuticals position peaked at $1.52B in Q4 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.